Equity Overview
Price & Market Data
Price: $6.61
Daily Change: +$1.12 / 16.94%
Daily Range: $5.77 - $7.30
Market Cap: $1,057,023,040
Daily Volume: 10,175,323
Performance Metrics
1 Week: 29.67%
1 Month: 23.60%
3 Months: 47.32%
6 Months: 79.84%
1 Year: 196.0%
YTD: 94.69%
Company Details
Employees: 394
Sector: Health technology
Industry: Biotechnology
Country:
Details
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.